HLB Pharmaceutical Co., Ltd.

A047920

KR7047920004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 12/05/2024 BST			5-day change	1st Jan Change
29,300 ^KRW	-3.62%		-5.02%	+92.64%

2023	HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors	CI
2023	HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors	CI

HLB Pharmaceutical Co., Ltd(KOSDAQ:A047920) added to S&P Global BMI Index

September 20, 2021 at 05:00 am

Latest news about HLB Pharmaceutical Co., Ltd.

HLB innoVation Co.,Ltd. announced that it has received KRW 55.99999522 billion in funding from a group of investors	12/03/23	CI
HLB innoVation Co.,Ltd. announced that it expects to receive KRW 55.99999522 billion in funding from a group of investors	31/01/23	CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.	09/08/22	CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.	08/08/22	CI
Verismo Therapeutics, Inc. announced that it expects to receive KRW 12.138369345 billion in funding from HLB Pharmaceutical Co., Ltd	05/04/22	CI
G-treeBNT Co., Ltd. announced that it has received KRW 95.000054256 billion in funding from a group of investors	15/11/21	CI
HLB Pharmaceutical Co., Ltd(KOSDAQ:A047920) added to S&P Global BMI Index	20/09/21	CI
HLB Therapeutics Co.,Ltd. announced that it expects to receive KRW 95.000054256 billion in funding from a group of investors	12/09/21	CI
Verismo Therapeutics, Inc. announced that it has received KRW 16.977 billion in funding from HLB Pharmaceutical Co., Ltd	26/04/21	CI
Verismo Therapeutics, Inc. announced that it expects to receive KRW 16.977 billion in funding from HLB Pharmaceutical Co., Ltd	28/03/21	CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 13.2 billion in funding	11/03/21	CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 13.2 billion in funding	09/02/21	CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 20 billion in funding from EBEST Investment & Securities Co., Ltd.	18/10/20	CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 20 billion in funding from HLB Co., Ltd. and other investor.	18/10/20	CI
Mediforum Pharmaceutical Incorporation announced that it has received KRW 48.632978215 billion in funding from EBEST Investment & Securities Co., Ltd., Medi Forum Co.,Ltd., HLB Co., Ltd.	09/09/20	CI
Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 20 billion in funding from HLB Co., Ltd. and other investor	30/08/20	CI
Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 20 billion in funding from Ibest Investment Company Ltd., Hanyang Securities Co. Ltd., Investment Arm, EBEST Investment & Securities Co., Ltd.	26/04/20	CI
Mediforum Will Collaborate with Supertrans in the Manufacturing and Commercialization of Supertrans' Products in Asia, Including South Korea, China, and Japan	07/04/20	CI
SuperTrans Medical announced that it expects to receive $2 million in funding from Mediforum Pharmaceutical Incorporation	06/04/20	CI
Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 9.90000095 billion in funding	23/02/20	CI
Mediforum Co.,Ltd. acquired 13.9% stake in C-TRI Co., Ltd. from DAE HWA Pharmaceutical Co., Ltd. and Wanjoo Kim for KRW 20.2 billion.	04/12/19	CI
Mediforum Pharmaceutical Incorporation announced that it expects to receive KRW 48.632978215 billion in funding from EBEST Investment & Securities Co., Ltd., Medi Forum Co.,Ltd., HLB Co., Ltd.	15/10/19	CI
DelSiTech Ltd and C-Tri Co. Ltd Sign Collaboration Agreement to Develop Innovative Drug Delivery Technology Product for Oncology	18/12/17	CI
C-TRI Co., Ltd. announced that it has received KRW 15 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, Synergy Partners Co., Ltd., Timefolio Co.,Ltd., Lime Asset Management Co., Ltd., ANDA Asset Management Co., Ltd.	27/07/16	CI
C-TRI Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, Synergy Partners Co., Ltd., Timefolio Co.,Ltd., Lime Asset Management Co., Ltd., ANDA Asset Management Co., Ltd.	26/07/16	CI

Chart HLB Pharmaceutical Co., Ltd.

Duration

Period

More charts

HLB Pharmaceutical Co Ltd, formerly Mediforum Pharmaceutical Inc, is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical products. The Company mainly manufactures and sells pharmaceutical products including cimetidine tablets, rozatin tablets, rabeprazole tablets, rozatinplus tablets, mosapia tablets and other ethical the counter (ETC) drugs; gynobetadine vaginal suppositories, and other over the counter (OTC) drugs; aceclofenac tablets, revotec tablets and other commissioned ETC drugs; L-carnitine tablets, elcatan tablets, hepatine liquids and other commissioned OTC drugs.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HLB PHARMACEUTICAL CO., LTD.	+92.64%	312M
ELI LILLY AND COMPANY	+29.98%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.52%	361B
MERCK & CO., INC.	+18.59%	329B
ABBVIE INC.	+4.07%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.09%	166B

Other Pharmaceuticals